- Home
- OMH vs OGEN Comparison
OMH vs OGEN Comparison
Compare OMH & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMH
- OGEN
- Stock Information
- Founded
- OMH 2015
- OGEN 1996
- Country
- OMH Singapore
- OGEN United States
- Employees
- OMH N/A
- OGEN N/A
- Industry
- OMH Real Estate
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- OMH Finance
- OGEN Health Care
- Exchange
- OMH Nasdaq
- OGEN Nasdaq
- Market Cap
- OMH N/A
- OGEN 4.6M
- IPO Year
- OMH 2023
- OGEN N/A
- Fundamental
- Price
- OMH $2.55
- OGEN $0.21
- Analyst Decision
- OMH Strong Buy
- OGEN
- Analyst Count
- OMH 1
- OGEN 0
- Target Price
- OMH $15.00
- OGEN N/A
- AVG Volume (30 Days)
- OMH 17.0K
- OGEN 340.9K
- Earning Date
- OMH 01-01-0001
- OGEN 05-14-2025
- Dividend Yield
- OMH N/A
- OGEN N/A
- EPS Growth
- OMH N/A
- OGEN N/A
- EPS
- OMH N/A
- OGEN N/A
- Revenue
- OMH $5,390,607.00
- OGEN N/A
- Revenue This Year
- OMH $111.47
- OGEN N/A
- Revenue Next Year
- OMH $32.08
- OGEN N/A
- P/E Ratio
- OMH N/A
- OGEN N/A
- Revenue Growth
- OMH 25.77
- OGEN N/A
- 52 Week Low
- OMH $0.25
- OGEN $0.19
- 52 Week High
- OMH $2.70
- OGEN $3.43
- Technical
- Relative Strength Index (RSI)
- OMH 63.16
- OGEN 26.93
- Support Level
- OMH $2.12
- OGEN $0.19
- Resistance Level
- OMH $2.31
- OGEN $0.22
- Average True Range (ATR)
- OMH 0.22
- OGEN 0.02
- MACD
- OMH -0.07
- OGEN -0.01
- Stochastic Oscillator
- OMH 23.38
- OGEN 15.11
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.